reason report
not-so-ordinari earn possibl head nov
bottom line key upcom catalyst -- advoc
anca-associ vasculitis/aav -- stock today
believ investor posit ahead data remain
optimist advoc believ may announc
earn nov given time close ye cogniz
investor reluct risk capit yet recent stock move
heel posit clinic data suggest posit advoc data may
engend meaning upsid meanwhil reminisc
shine data anticip ifrx mp trade sympathi base
read-through advoc reiter op pt
advoc top-lin result may potenti coincid
earn wherea enrol advoc announc
complet earn pr updat recruit statu
 activ recruit post sept link back-
of-the-envelop math impli studi complet mid-sept
factoring-in week period data analysi data may avail
earli nov coincid earn releas
survey variou trial report posit result
correspond stock move see upsid exhibit
caveat investor sentiment expect lead
data result wide rang stock move low high
nevertheless believ could move significantli
higher posit advoc data ye horizon
investor may open capit alloc -- let alon risk capit
ahead advoc data -- think posit outcom could
see capit inflow investor sentiment take posit turn
receptor inhibitor approach prospect avacopan
commerci drug may appeal addit group investor
point investor appetit de-risk program clearli exemplifi
two recent announc -- op op
stock respect shortli unexpect
announc believ similar influx interest capit may
possibl posit data
recent ifrx price action may reflect investor sentiment
advoc sinc hit low ifrx gain
move yesterday coincident
announc earn date nov yesterday believ
time intrigu climb ifrx given similar biolog
target ifrx ligand receptor may
reflect investor grow optim advoc may provid
potenti read-through ifrx prospect aav despit
shine result ifrx embark trial aav advoc
blend revenu multipl
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
outcom could provid meaning read-through ifrx program
valuat ifrx may cheaper stock
remain optimist advoc posit data may fuel
higher-than-anticip move upsid reason discuss
preview link kol event link believ
avacopan demonstr non-inferior soc
howev believ investor may will ascrib even higher
valu due avacopan potenti pipeline-in-a-drug date
awar least three indic investig avacopan
aav glomerulopathi hidraden suppurativa hs
although last program still draw investor skeptic follow ifrx
shine data moreov seen spike activ surround
compani proprietari platform develop drug
complement space link link necessarili classifi
complement-target compani target
chemokin receptor investor may draw comparison
de-risk proprietari chemistri platform seen
achn mp rarx mp consider remind
investor takeout valu achn rarx
higher current valuat
rate share outperform clinical-stag biotechnolog compani leverag
oral administ small molecul inhibit chemokin chemoattract receptor much
ccxi valuat hing lead compound avacopan formerli potent
inhibitor receptor evalu multipl mid-to-l stage clinic
trial see upcom advoc data anca-associ vascul aav
expect key binari catalyst compani well valid
druggabl target behind aav potenti posit outcom follow-on indic
glomerulopathi hidraden suppurativa hs may render avacopan pipelin
within drug despit mani uncertainti unknown complement biolog
believ alxn op success set import preced sinc chemokin
complement system far-reach implic human health avacopan success could
lead posit read-through ccxi earlier-stag asset asset
long term de-risk avacopan could lead investor appreci
ccxi proprietari platform may eventu tap preval competit
indic inflammatori bowel diseas ibd oncolog valuat
limit ccxi orphan program
deriv one-year pt base blend dcf analysi revenu
multipl analysi assign valu probability-weight sale avacopan po
anca-associ vascul aav glomerulopathi hidraden
suppurativa hs sale po focal segment glomerulosclerosi
fsg addit indic clinic asset earlier-stag candid
repres upsid estim matur clinical-stag compani use discount
rate termin growth rate repres market capit
clinical-stag compani risk includ clinic regulatori financi
lead asset avacopan add signific binari risk head data readout even
though evalu multipl indic guarante program
understand complement system diseas still evolv success
particular indic may translat success indic
clinic risk associ clinic candid
exhibit stock move ensu posit data catalyst also
companytickerd event changesag therapeut medicin inc
collabor licens revenu
total incom expens
chang cash
proce common stock
proce convert note/debt
proce warrant
discount rate/cost equiti
